Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
BEIJING, Dec. 16, 2021 /PRNewswire/ -- Akso Health Group ("Akso Health", the "Company" or "We") (NASDAQ:AHG), formerly known as Xiaobai Maimai Inc., today announced that the Company will update its name and ticker symbol on the Nasdaq Stock Market, effective at the start of trading on December 16, 2021 (the "Effective Date"). On the Effective Date, the Company's ADS and ordinary shares will be quoted under the new name "Akso Health Group" which was previously approved by the Company's shareholders (the "Name Change"), and the Company's ticker symbol will be updated to "AHG". Ms. Yilin Wang, Chairwoman and Chief Executive Officer of Akso Health, commented, "We are excited to align our Nasdaq
BEIJING, Dec. 15, 2021 /PRNewswire/ -- Akso Health Group (NASDAQ:AHG) ("Akso Health", the "Company" or "we"), formerly known as Xiaobai Maimai Inc., a social e-commerce platform in China, today announced its unaudited condensed consolidated financial results for the six months ended September 30, 2021. The Company amended the ratio of ADS and ordinary shares from one (1) ADS representing one (1) ordinary share to one (1) ADS representing three (3) ordinary shares, effective as of August 24, 2020. Fiscal year refers to the 12-month period ended March 31. First Half of Fiscal Year 2022 Highlights Number of Average Monthly Mobile Active Users[1] for the six months ended September 30, 2021 was 8
BEIJING, Dec. 3, 2021 /PRNewswire/ -- Xiaobai Maimai Inc. (NASDAQ:HX) ("Xiaobai Maimai" or the "Company"), today announced that it held the 2021 annual general meeting of shareholders (the "AGM") at the Meeting Room, Futian Shangri-La, 4088 Yi Tian Road, Futian District, Shenzhen 518408, People's Republic of China, at 10:00 a.m. (Beijing Time) on December 3, 2021. At the AGM, holders of 71,057,650 ordinary shares (including ordinary shares represented by the Company's American Depositary Shares), out of the 71,478,550 ordinary shares issued and outstanding, were present in person or by proxy, and therefore constituted a quorum of more than one-third of the ordinary shares outstanding and ent
424B3 - Xiaobai Maimai Inc. (0001702318) (Filer)
6-K - Xiaobai Maimai Inc. (0001702318) (Filer)
6-K - Xiaobai Maimai Inc. (0001702318) (Filer)
SC 13D - Xiaobai Maimai Inc. (0001702318) (Subject)
SC 13G/A - Xiaobai Maimai Inc. (0001702318) (Subject)
SC 13G/A - Xiaobai Maimai Inc. (0001702318) (Subject)
BEIJING, Dec. 15, 2021 /PRNewswire/ -- Akso Health Group (NASDAQ:AHG) ("Akso Health", the "Company" or "we"), formerly known as Xiaobai Maimai Inc., a social e-commerce platform in China, today announced its unaudited condensed consolidated financial results for the six months ended September 30, 2021. The Company amended the ratio of ADS and ordinary shares from one (1) ADS representing one (1) ordinary share to one (1) ADS representing three (3) ordinary shares, effective as of August 24, 2020. Fiscal year refers to the 12-month period ended March 31. First Half of Fiscal Year 2022 Highlights Number of Average Monthly Mobile Active Users[1] for the six months ended September 30, 2021 was 8
BEIJING, Dec. 3, 2021 /PRNewswire/ -- Xiaobai Maimai Inc. (NASDAQ:HX) ("Xiaobai Maimai" or the "Company"), today announced that it held the 2021 annual general meeting of shareholders (the "AGM") at the Meeting Room, Futian Shangri-La, 4088 Yi Tian Road, Futian District, Shenzhen 518408, People's Republic of China, at 10:00 a.m. (Beijing Time) on December 3, 2021. At the AGM, holders of 71,057,650 ordinary shares (including ordinary shares represented by the Company's American Depositary Shares), out of the 71,478,550 ordinary shares issued and outstanding, were present in person or by proxy, and therefore constituted a quorum of more than one-third of the ordinary shares outstanding and ent
BEIJING, Oct. 22, 2021 /PRNewswire/ -- Xiaobai Maimai Inc. (NASDAQ:HX) ("Xiaobai Maimai," the "Company," or "we"), today announced the appointment of Dr. Yingxian Liu as the medical consultant to the Company. Dr. Liu will work closely with management to develop the Company's cancer therapy and radiation oncology business by the Company's wholly-owned subsidiary, We Health Limited. Dr. Liu received his medical degree from Sun Yat-sen University of Medical Sciences in Guangzhou, China. He completed his pathology residency at North Shore University Hospital in Manhasset, New York. Dr. Liu completed his hematopathology fellowship at Albert Einstein College of Medicine at Montefiore Medical Cente